Kadmon (NYSE:KDMN) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Kadmon (NYSE:KDMNGet Rating) in a note issued to investors on Wednesday. The brokerage set a “sell” rating on the stock.

Shares of KDMN opened at $9.50 on Wednesday. The company’s 50-day moving average is $9.50. Kadmon has a 1-year low of $3.19 and a 1-year high of $9.50.

Kadmon Company Profile (Get Rating)

Kadmon is a clinical-stage biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. Its clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies.

Recommended Stories

Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.